Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates using diverse protein-engineering methods. The company utilizes a proprietary single-domain antibody (sdAb) platform that enables construction of molecules containing multiple binding units with defined valency or multiple specificities. Its pipeline targets oncology, orphan diseases and infectious diseases and includes three clinical-stage programs with two additional programs expected to enter the clinic this year. Inhibrx intends to use new funding to advance these clinical programs and further develop its sdAb platform. Financially, the company has received approximately $205M since inception, comprising about $135M in investor equity and debt and $70M in licensing and grant payments. Most recently it received a $40M investment from Viking Global Investors, which joined existing investors RA Capital, Lilly Asia Ventures, ArrowMark Partners, WuXi Biologics and Alexandria.

Total raised

$40M

Funding rounds

1

Latest round

Equity

Latest activity

May 2019